Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Abroad (travel likely)RecruitingPHASE2

Conditions

Muscle-Invasive Bladder Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ghent University Hospital, Ghent, Belgium
Contact: Study coordinator (Valerie Fonteyne) · valerie.fonteyne@uzgent.be · +3293323015

Study leads

Valerie Fonteyne, MD; PhD
Principal Investigator
UZ Ghent

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

Muscle-Invasive Bladder Carcinoma · Tumor

Abroad (travel likely)RecruitingPHASE2

Los Angeles, United States

RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients

Bladder Cancer · Muscle-Invasive Bladder Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Guangzhou, China

Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer

Muscle-Invasive Bladder Carcinoma

Abroad (travel likely)RecruitingPHASE2

Roma, Italy

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Localized Muscle Invasive Bladder Urothelial Carcinoma · Muscle-Invasive Bladder Carcinoma

Abroad (travel likely)RecruitingPHASE1

Cleveland, United States